Heterocyclic Compounds

Matches 651 - 700 out of 37,044	< 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 >

Document	Document Title
WO/2023/207283A1	COMPOUNDS AS PARP1 INHIBITIORS Disclosed herein is the compounds and pharmaceutically acceptable salts thereof that inhibit the Poly (ADP-ribose) polymerase (PARP) family of enzymes. The present disclosure also relates to the use of these compounds or pharmaceutically...
WO/2023/212535A1	FGFR2 INHIBITOR COMPOUNDS The present invention provides compounds of the formula (I):, or a pharmaceutically acceptable salt thereof, wherein A, X1, X2, X3, Y, Z, Z1, Z2, R2 and R6 are as defined herein, for use in the treatment of cancer and a method of treatin...
WO/2023/212693A1	ALLOSTERIC CHROMENONE INHIBITORS OF PHOSPHOINOSITIDE 3-KINASE (PI3K) FOR THE TREATMENT OF DISEASE The disclosure relates to compounds of Formula (I) as allosteric chromenone inhibitors of phosphoinositide 3 kinase (PI3K) useful in the treatment of diseases or disorders associated with PI3K modulation, Formula (I): (I) or pharmaceutic...
WO/2023/209062A1	SOLID FORM OF 3-((1R,3R)-1-(2,6-DIFLUORO-4-((1-(3- FLUOROPROPYL)AZETIDIN-3-YL)AMINO)PHENYL)-3-METHYL-1,3,4,9- TETRAHYDRO-2H-PYRIDO[3,4-B]INDOL-2-YL)-2,2-DIFLUOROPROPAN-1-OL TARTRATE The present invention relates to a crystalline form of giredestrant tartrate having an improved particle size distribution, as well as to processes for its preparation, pharmaceutical compositions comprising it, and its use as a medicament.
WO/2023/209441A1	IMIDAZO[4,5-C]PYRIDINE DERIVATIVE COMPOUNDS AS TLR7/8 MODULATORS Disclosed herein are immune response modulators that act on toll-like receptors and methods of use thereof.
WO/2023/212240A1	COMPOUNDS FOR INHIBITING KIF18A The present disclosure relates generally to inhibitors of KIF18A, compositions thereof, and methods of using said compounds and compositions thereof. More specifically, the present disclosure relates to inhibitors of KIF18A and methods o...
WO/2023/208174A1	DEUBIQUITINASE INHIBITOR AND USE THEREOF The present invention relates to a compound represented by formula (I) or a racemate, a stereoisomer, a tautomer, an isotope-labeled form, an N-oxide, a solvate, a polymorph, a metabolite, an ester, a pharmaceutically acceptable salt or ...
WO/2023/209084A1	CONDENSED BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER The specification relates to compounds of Formula (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in the tre...
WO/2023/212071A1	COMBINATION AND THE USE THEREOF Provided here is a method of treating a cancer in a subject in need thereof, comprising administering to said subject a combination comprising: (i) about 5 mg, about 10 mg, about 15 mg, about 20 mg, about 25 mg, about 30 mg, about 35 mg,...
WO/2023/210599A1	COMPOUND SERVING AS DDR1 KINASE INHIBITOR, AND MEDICINE The present invention provides a compound represented by general formula[1] and having a DDR1 kinase inhibitory activity, a pharmaceutically acceptable salt of the compound, or a solvate of the compound or the pharmaceutically acceptable...
WO/2023/212147A1	HETEROCYCLIC COMPOUNDS AS MODULATORS OF BCL6 AS LIGAND DIRECTED DEGRADERS Provided herein are compounds and compositions thereof for modulating BCL6. In some embodiments, the compounds and compositions are provided for treatment of cancer or an autoimmune disease.
WO/2023/208124A1	PIPERIDINE CARBOXAMIDE AZAINDANE DERIVATIVE, METHOD FOR PREPARING SAME, AND USE THEREOF The present application relates to a substituted piperidine carboxamide azaindane derivative, a method for preparing same, and use of a pharmaceutical composition containing the derivative or a deuterated derivative in medicine. Specific...
WO/2023/209086A1	BICYCLIC HETEROAROMATIC COMPOUNDS FOR TREATING CANCER The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...
WO/2023/208092A1	TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF The disclosure relates to tricyclic heterocyclic derivatives as shown in Formula (I), to pharmaceutical compositions comprising them, to a process for their preparation, and their use as therapeutic agents.
WO/2023/210623A1	HALOALKYL SULFONE ANILIDE COMPOUND AND HERBICIDE CONTAINING SAME The present invention is a novel haloalkyl sulfone anilide compound or a salt thereof, an herbicide composition including said compound or salt thereof, an herbicide method including a step for applying the herbicide composition, and a m...
WO/2023/210740A1	BENZOTHIOPHENE COMPOUND The present invention addresses the problem of providing a medicinal drug that can treat and/or prevent diseases linked to oxidative stress, by inhibiting the protein-protein interaction between Keap1 and Nrf2 to activate Nrf2. The prese...
WO/2023/209651A1	BICYCLE COMPOUNDS AS TEAD INHIBITOR The present invention relates to bicyclic heterocycle compounds, to their preparation and to their therapeutic use. Specifically, the present invention relates to the compounds represented by formula (I), a pharmaceutically acceptable sa...
WO/2023/207937A1	SALT FORM AND CRYSTAL FORM OF BIPHENYL COMPOUND AS IMMUNOMODULATOR AND METHOD FOR PREPARING SAME Disclosed are a salt form and a crystal form of a biphenyl compound (I) as an immunomodulator, and a method for preparing same. Also disclosed is use of the salt form and the crystal form in preparing a related drug for the immunomodulator.
WO/2023/212612A2	CERTAIN CHEMICAL ENTITIES, COMPOSITIONS, AND METHODS Provided herein are inhibitors of c-KIT kinase, pharmaceutical compositions comprising said inhibitory compounds, and methods for using said c-KIT kinase inhibitory compounds for the treatment of cancer, inflammatory, allergic, or autoim...
WO/2023/209368A1	NITROGEN COMPRISING HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF DISORDERS ASSOCIATED WITH GPR55 RECEPTOR The present invention provides compounds of formula (I) and pharmaceutically acceptable salts, solvates and prodrugs thereof: Formula (I) wherein n, R1, R2, R3, R4, R5, A1, A2, A3, A4 and A5 are as defined in the specification, processes...
WO/2023/209090A1	BICYCLIC HETEROAROMATIC COMPOUNDS AND THEIR APPLICATION IN THE TREATMENT OF CANCER The specification relates to compounds of Formula (I): (I) and to pharmaceutically acceptable salts thereof, to processes and intermediates used for their preparation, to pharmaceutical compositions containing them and to their use in th...
WO/2023/208127A1	HETEROARYL-SUBSTITUTED BICYCLIC COMPOUND AND USE THEREOF Disclosed are a series of heteroaryl-substituted bicyclic compounds and use thereof, and particularly, disclosed are a compound represented by formula (P), a stereoisomer thereof, and a pharmaceutically acceptable salt thereof.
WO/2023/206580A1	DURLOBACTAM CRYSTALLINE FORMS Provided herein are salt forms of Durlobactam (DUR) having the Formula I: In particular, crystalline forms of a DUR-TBA, a DUR-TEA, and a DUR-Ca are provided. The methods of preparing these salts, and characterization of their various po...
WO/2023/207284A1	PIPERAZINE DERIVATIVES AS PARP1 INHIBITIORS Disclosed are piperazine derivatives and pharmaceutically acceptable salts thereof that inhibit the Poly (ADP-ribose) polymerase (PARP) family of enzymes. Also disclosed is the use of these compounds or pharmaceutically acceptable salts ...
WO/2023/211990A1	BICYCLIC HETEROCYCLIC AMIDE INHIBITORS OF NA V1.8 FOR THE TREATMENT OF PAIN Provided herein are compounds of formula (I), pharmaceutical compositions comprising the compounds, methods of preparing the compounds, and methods of using the compounds and compositions in treating conditions associated with voltage-ga...
WO/2023/207992A1	INDOLE DERIVATIVE, ORGANIC ELECTROLUMINESCENT ELEMENT, DISPLAY DEVICE, AND LIGHTING DEVICE The present invention relates to an indole derivative, an organic electroluminescent element, a display device, and a lighting device. The indole derivative of the present invention has a relatively high triplet level and a high glass tr...
WO/2023/207911A1	BICYCLIC HETEROCYCLIC COMPOUND, PHARMACEUTICAL COMPOSITION AND APPLICATION Disclosed are a bicyclic heterocyclic compound, a pharmaceutical composition and an application. Specifically, a compound represented by formula I, a pharmaceutically acceptable salt thereof, a solvate thereof, or a solvate of the pharma...
WO/2023/207875A1	CDK INHIBITORS, PHARMACEUTICAL COMPOSITIONS, AND THERAPEUTIC APPLICATIONS Provided herein are CDK inhibitors, e.g., a compound of Formula (I), and pharmaceutical compositions thereof. Also provide herein is a method of their use for treating, preventing, or ameliorating a chemotherapy-induced gastrointestinal ...
WO/2023/211238A1	HETEROARYL DERIVATIVE COMPOUND AND USE THEREOF The present invention relates to a heteroaryl derivative and use thereof. The heteroaryl derivative of the present invention exhibits excellent inhibitory activity against EGFR, and thus is useful as a therapeutic agent for EGFR-related ...
WO/2023/205595A2	EGFR INHIBITORS IN CANCER TREATMENT The present invention is directed to the compounds of Formula (A) inhibitors of EGFR. The inhibitors described herein can be useful in the treatment of diseases or disorders associated with EGFR, such as is lung cancer. In particular, th...
WO/2023/202626A1	FUSED PYRIDAZINONE COMPOUND AS PRMT5 INHIBITOR The present invention provides a PRMT5 inhibitor as shown in formula (I), or a pharmaceutically acceptable salt, an isotopic variant, a tautomer, a stereoisomer, a prodrug, a polymorph, a hydrate or a solvate thereof. The present inventi...
WO/2023/202623A1	POLQ INHIBITOR COMPOUND AND USE THEREOF Provided in the present invention are a POLQ inhibitor compound represented by formula (I) or a pharmaceutically acceptable salt thereof, a pharmaceutical composition containing same, and use thereof in preparing a drug for preventing or...
WO/2023/205645A1	BICYCLIC COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2023/205701A1	MACROCYCLIC HETEROCYCLES AND USES THEREOF The present disclosure provides compounds and pharmaceutically acceptable salt thereof, and methods of using the same. The compounds and methods have a range of utilities as therapeutics, diagnostics, and research tools. In particular, t...
WO/2023/205653A1	BICYCLIC COMPOUNDS Provided herein are compounds of Formula (I), or pharmaceutically acceptable salts thereof, pharmaceutical compositions that include a compound described herein (including pharmaceutically acceptable salts of a compound described herein)...
WO/2023/201780A1	METHOD FOR PREPARING QUINOLONE COMPOUND AND INTERMEDIATE THEREOF Provided is a method for preparing a quinolone compound and an intermediate thereof, particularly, a method for preparing quinolone and a pharmaceutical quinolinone intermediate. Specifically, provided are a method for preparing a compou...
WO/2023/274324A9	NITROGEN-CONTAINING HETEROCYCLIC COMPOUND, AND PREPARATION METHOD THEREFOR, INTERMEDIATE THEREOF, AND APPLICATION THEREOF Disclosed in the present invention are a nitrogen-containing heterocyclic compound, and a preparation method therefor, an intermediate thereof, and an application thereof. The present invention provides a nitrogen-containing heterocyclic...
WO/2023/205680A1	PI3Kα INHIBITORS The present disclosure provides compounds, compositions, and methods useful for inhibiting PI3Kα, and/or treating a disease, disorder, or condition associated with PI3Kα, and/or treating cancer.
WO/2023/203174A1	HETEROCYCLIC CULLIN RING UBIQUITIN LIGASE COMPOUNDS AND USES THEREOF The present invention relates to compounds with the ability to modulate/stimulate/induce, particularly induce degradation of a target protein/target proteins. Such target protein/ target proteins may be proteins involved in diseases, lik...
WO/2023/203163A1	COMPOUNDS INDUCING PRODUCTION OF PROTEINS BY IMMUNE CELLS The present invention relates to a compound of formula (I) and its use in the production of interleukin-10 by immune cells. The invention also relates to induced immune cells capable of producing interleukin 10. The invention also relate...
WO/2023/205251A1	COMPOUNDS ACTIVE TOWARDS BROMODOMAINS Disclosed are compounds of formula (I) which modulate bromodomains, pharmaceutical compositions containing said compounds and use of said compounds in therapy.
WO/2023/205415A1	TRANSCRIPTION FACTOR EB ACTIVATORS AND USES THEREOF Provided are pharmaceutical compositions comprising a pharmaceutically acceptable carrier or diluent and a compound represented by Formula (I): or pharmaceutically acceptable salts thereof, which are useful for the activation of TFEB and...
WO/2023/205463A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/202687A1	PYRAZINONE DERIVATIVE AND USE THEREOF IN MEDICINE The present invention relates to a compound as represented by general formula (A) or a stereoisomer, a deuterated substance, a solvate, a prodrug, a metabolite, a pharmaceutically acceptable salt or a cocrystal thereof, an intermediate t...
WO/2023/205778A1	HETEROARYL COMPOUNDS FOR THE TREATMENT OF PAIN Compounds, and pharmaceutically acceptable salts thereof, useful as inhibitors of sodium channels are provided. Also provided are pharmaceutical compositions comprising the compounds or pharmaceutically acceptable salts and methods of us...
WO/2023/205764A1	OPIOID RECEPTOR AGONIST AND METHODS OF USE THEREOF The present disclosure relates to compounds of formula I that can bind to one or more opioid receptors. In one aspect, the compounds described herein can bind to the kappa opioid receptor (KOR) and behave as an opioid receptor agonist. T...
WO/2023/205074A1	PROCESSES AND INTERMEDIATES FOR SYNTHESIS OF ADAGRASIB The present invention relates to new synthetic routes of synthesizing adagrasib. The invention also provides intermediates used in the provided synthetic routes.
WO/2023/198114A1	ALK2 KINASE INHIBITOR An ALK2 kinase inhibitor as represented by general formula (I), a pharmaceutical composition thereof, a preparation method therefor, and use of the ALK2 kinase inhibitor in preparing a drug for the prevention and/or treatment of indicati...
WO/2023/198195A1	CONJUGATE COMPRISING TOLL-LIKE RECEPTOR AGONIST Disclosed herein are compounds that are Toll-like receptor (TLR) agonist, conjugates comprising these compounds and cell targeting moiety, pharmaceutical compositions thereof, method of activating toll-like receptors 7 and/or 8 and metho...
WO/2023/198181A1	CARBOBICYCLIC NUCLEOSIDES FOR TREATMENT OF VIRAL INFECTION Carbobicyclic nucleoside compounds useful for the treatment of coronavirus disease 2019 (COVID-19), RSV and other viral infections are provided. The carbobicyclic nucleoside compound may be a compound as set forth herein. Pharmaceutical ...

Matches 651 - 700 out of 37,044	< 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 >